Glaucomatous vision loss can occur without symptoms or warning, making proactive imaging essential to halt progression and safeguard a patient’s vision.
Glaucoma refers to a group of eye conditions that damage the optic nerve, the vital link between the eye and the brain. Often caused by abnormally high pressure in the eye, this damage affects the million-plus delicate nerve fibers that transmit visual data. The disease typically begins by eroding peripheral vision and is known as the “silent thief of sight,” as patients often do not notice vision loss until it reaches an advanced stage or leads to “tunnel vision.”
Early detection is paramount because vision lost to glaucoma is permanent and cannot be restored. Structural damage to the optic nerve frequently occurs long before a patient experiences functional visual field loss. By the time symptoms appear, significant and irreversible damage has already taken place. Timely evaluation allows for early intervention and treatment plans that can halt the disease and protect the patient’s sight.
Our technology identifies structural indicators of glaucoma, such as optic disc cupping and bayoneting, during routine retinal exams*. By helping flag these suspected signs of nerve damage, the platform provides a critical safety net that catches cases that might otherwise go undetected in a primary care setting. Such patients can be referred to specialists for the additional testing and management needed to preserve their vision.
*Autonomous glaucomatous optic nerve damage detection is limited to investigational use in the US by federal law.
Prevent vision loss
Extend eyecare access
Generate preventive care revenue
Reduce downstream cost
Improve healthcare quality metrics
Same platform
Same camera(s)
Same workflow
New diseases/cameras with added clearances
Learn more about our full-spectrum solution.
See the proof with your own eyes.
FDA 510(k)-cleared: The only autonomous AI for simultaneous mtmDR and vtDR detection
mtmDR accuracy: 96% sensitivity and 88% specificity for identifying more than mild DR
vtDR accuracy: 97% sensitivity and 90% specificity for identifying vision-threatening disease
Global clearances: EU MDR Class IIb for autonomous detection of DR, AMD, and glaucomatous optic nerve damage
Secure and certified: SOC 2 Type 2 attestation, HIPAA, GDPR, and ISO 13485:2016 (MDSAP) compliant for maximum data safety
Camera compatibility: Indicated for use with multiple retinal camera models from leading camera manufacturers
View the clinical evidence for yourself.
Start FDA-cleared autonomous diabetic retinopathy screening in your clinic today.
